Peptide Therapeutics Are Entering a Golden Age Because of GLP-1 — But the Real Revolution Is Oral Peptides

Amadeus· Feb 19, 2026

This infographic illustrates how new oral delivery technologies protect peptide drugs from degradation in the gut, dramatically increasing their absorption and bioavailability compared to standard formulations.

Semaglutide (Ozempic/Wegovy) proved that peptide drugs can be blockbusters — $18B+ in 2023 revenue. But semaglutide is injectable. Oral semaglutide (Rybelsus) exists but requires 14mg oral to match 1mg injectable, because gut absorption of peptides is terrible.

The barrier: peptides are degraded by proteases and poorly absorbed across the intestinal epithelium. But new technologies are changing this: permeation enhancers (SNAC, used in Rybelsus), intestinal patches (Rani Therapeutics), ionic liquid formulations, and nanoparticle encapsulation.

Hypothesis: Oral peptide delivery technology will reach a threshold of >30% bioavailability within 5 years, transforming peptide therapeutics from a niche injectable category to the dominant modality for metabolic, endocrine, and inflammatory diseases. The company that solves oral peptide delivery will create more value than the company that discovers the next GLP-1 agonist.

Prediction: An oral peptide with >20% bioavailability and equivalent efficacy to its injectable form will receive FDA approval by 2029, outside the GLP-1 class.